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Cystic fibrosis (CF) patients harboring the most common deletion mutation of the CF trans-
membrane conductance regulator (CFTR), F508del, are poor responders to potentiators of
CFTR channel activity which can be used to treat a small subset of CF patients who genet-
ically carry plasma membrane (PM)-resident CFTR mutants. The misfolded F508del-CFTR
protein is unstable in the PM even if rescued by pharmacological agents that prevent its
intracellular retention and degradation. CF is a conformational disease in which defective
CFTR induces an impressive derangement of general proteostasis resulting from disabled
autophagy. In this review, we discuss how rescuing Beclin 1 (BECN1), a major player of
autophagosome formation, either by means of direct gene transfer or indirectly by adminis-
tration of proteostasis regulators, could stabilize F508del-CFTR at the PM. We focus on the
relationship between the improvement of peripheral proteostasis and CFTR PM stability
in F508del-CFTR homozygous bronchial epithelia or mouse lungs. Moreover, this article
reviews recent pre-clinical evidence indicating that targeting the intracellular environment
surrounding the misfolded mutant CFTR instead of protein itself could constitute an attrac-
tive therapeutic option to sensitize patients carrying the F508del-CFTR mutation to the
beneficial action of CFTR potentiators on lung inflammation.
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INTRODUCTION
The proteostasis network ensures intracellular homeostasis in spite
of genetic or epigenetic changes in protein conformation, extracel-
lular stress, or aging-associated perturbations (Balch et al., 2008;
Hutt et al., 2009; Powers et al., 2009; Gidalevitz et al., 2010; Hutt
and Balch, 2010; Roth and Balch, 2011). The accumulation of
misfolded/modified proteins due to mutations or due to the aging-
related decline of proteostasis contributes to several human con-
formational diseases including neurodegenerative disorders and
type II diabetes (Balch et al., 2008; Powers et al., 2009; Gidalevitz
et al., 2010; Roth and Balch, 2011).
Cystic fibrosis (CF), the most common life-threatening genetic
disease among Caucasians, constitutes the quintessential example
of a “conformational disease” (Balch et al., 2011; Okiyoneda et al.,
2011). CF is caused by mutations of the CF transmembrane con-
ductance regulator (CFTR) gene that encodes a cAMP-regulated
chloride channel primarily located at the apical membrane of
epithelial cells (Quinton, 1999; Welsh et al., 2001; Park et al., 2010).
Although more than1800 different mutations have been identified,
one single deletion of phenylalanine at position 508 (F508del-
CFTR), occurs in about 70–90% of CF patients in Northern
Europe and North America (Bobadilla et al., 2002). F508del-CFTR
protein can still retain a partial chloride channel activity if rescued
at the epithelial surface. However, due to its misfold, F508del-
CFTR does not reach the plasma membrane (PM) and is pre-
maturely degraded, thus provoking local inflammation, increased
susceptibility to respiratory bacterial infections, and progressive
pulmonary and digestive insufficiency (O’Sullivan and Freedman,
2009; Ratjen, 2009).
The birth prevalence of CF is estimated to be one in 3500–4500,
with 200-300 new cases each year in Europe. The typical form
of CF is diagnosed during early childhood and is characterized
by recurrent pulmonary infections, pancreatic insufficiency, and
elevated chloride concentrations in sweat. Although CF is a sys-
temic disease, the main cause of death is persistent and untreatable
pulmonary Pseudomonas aeruginosa infection. Loss of functional
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CFTR expression is thought to disturb the balance between fluid
secretion and absorption into the epithelial layer, leading to net
volume depletion of mucus, increased viscosity, and ineffective
bacterial clearance. Bacterial infection in turn induces an increased
inflammatory response and signaling, thus fueling a vicious cycle
of mucus retention, infection, and inflammation.
Mounting evidences indicate that a constitutive inflamma-
tory condition characterizes CF airways regardless of bacter-
ial exposure. CFTR dysfunction results in constitutive, elevated
NF-κB activation resulting in increased production of the pro-
inflammatory chemokine, interleukin-8 (Vij et al., 2009; Belcher
and Vij, 2010; Bodas and Vij, 2010; Hunter et al., 2010). Moreover,
the lack of functional CFTR in macrophages has been reported to
increase their responsiveness to inflammatory stimuli via uncon-
trolled TLR4 signaling (Bruscia et al.,2009,2011) and to affect their
capacity to kill Pseudomonas aeruginosa (Di et al., 2006; Deriy et al.,
2009; Zhang et al., 2010; Del Porto et al., 2011). These findings sup-
port the role of CFTR dysfunction in favoring bronchopulmonary
inflammation.
Advances in CF treatment have increased the median predicted
survival age from less than 5 years in the 1940s to over 37 years
presently (Davis, 2006). In addition to therapeutic approaches that
target cellular events downstream of the CFTR defect (Mozzillo
et al., 2009; Anderson, 2010; Belcher and Vij, 2010; Ratjen and
Grasemann, 2012), other strategies focused on the basic CFTR
defect have emerged (Riordan, 2008; Sloane and Rowe, 2010; Ama-
ral, 2011; Lukacs and Verkman, 2012). To date, gene therapy has
failed to demonstrate a clinical benefit for CF (Riordan, 2008;
Amaral, 2011). Thus, pharmacological strategies aimed at correct-
ing mutation-specific CFTR defects (CFTR-repairing therapies)
have gained a prominent role in CF drug discovery.
The still partially functional F508del-CFTR protein can be res-
cued at the PM by means of experimental low thermal conditions
(Denning et al., 1992), as well as by so-called correctors, which
are molecules that avoid the intracellular retention and degrada-
tion of F508del-CFTR protein (Pedemonte et al., 2005; Verkman
et al., 2006;Verkman and Galietta,2009), as extensively reviewed by
Molinski et al. and Pedemonte et al. in other chapters of this Special
Topic. A number of CFTR corrector molecules have been identified
by high-through put screening (Galietta et al., 2001; Pedemonte
et al., 2005; Van Goor et al., 2006, 2011). Several CFTR correctors
have proved their efficacy in rescuing F508del-CFTR in vitro. How-
ever, their efficacy in ameliorating the CF lung phenotype, either
in pre-clinical models or in CF patients, has not yet established.
A recent clinical trial with the most promising CFTR correc-
tor, VX-809 (Van Goor et al., 2011), in F508del-CFTR homozy-
gous patients demonstrated modest dose-dependent reductions
in sweat chloride (Clancy et al., 2012). However, beyond this
laboratory parameter, no improvement in lung function or CF
complications was reported (Clancy et al., 2012; Elborn, 2012).
The pool of F508del-CFTR molecules that can reach the PM
after treatment with currently available corrector molecules is
unstable. This instability can be explained by carboxyl-terminus
heat shock cognate 70 (HSP70)–interacting protein (CHIP)-
mediated Ubiquitination of F508del-CFTR (Okiyoneda et al.,
2010), followed by redirection of the protein from endosomal
recycling toward lysosomal delivery and subsequent degradation
(Sharma et al., 2004; Okiyoneda et al., 2010). This seminal obser-
vation of Lukacs’ group can explain why CF patients carrying
the misfolded F508del-CFTR respond poorly to molecules that
increase the activity of CFTR channel (CFTR potentiator) (Davis,
2011; Ramsey et al., 2011). Indeed, the rescued F508del-CFTR is
no longer available at the PM for the action of CFTR potentiators.
Therefore, combining CFTR correctors and potentiators may be
a suitable approach for F508del-CFTR patients, provided that the
corrector molecules are effective in increasing F508del-CFTR PM
stability after rescue. Currently, phase II clinical studies evaluat-
ing the combination of VX-809 and the potentiator VX-770 in CF
patients that express F508del-CFTR are underway (Elborn, 2012).
Restoration of a functional proteostasis network by the admin-
istration of proteostasis regulators (PRs) has emerged as a novel
approach to correct protein misfolding in conformational diseases
(Mu et al., 2008; Powers et al., 2009; Gidalevitz et al., 2010; Balch
et al., 2011). Therefore, strategies aiming at manipulating periph-
eral proteostasis could represent a promising area of research in
CF drug discovery. Understanding the mechanisms underlying the
derangement of proteostasis consequent to defective CFTR func-
tion could help improving the search of new drug candidates for
CF patients carrying F508del-CFTR mutants.
THREE TO TANGO IN CYSTIC FIBROSIS: CFTR,
TRANSGLUTAMINASE 2, AND AUTOPHAGY
DEFECTIVE CFTR FUNCTION PERTURBS THE POST-TRANSLATIONAL
NETWORK OF CF EPITHELIAL CELLS
An impressive derangement of cellular homeostasis takes place
in CF airways. Tissue transglutaminase (TG2) is upregulated in
CF epithelial cells at the transcriptional and even more at the
post-transcriptional levels (Maiuri et al., 2008). TG2 is a versa-
tile multifunctional protein that changes its function depending
on external and internal signals (Nurminskaya and Belkin, 2012).
In the presence of high Ca2+ levels, TG2 works as a crosslink-
ing enzyme, catalyzing several post-translational modifications of
target proteins. At low Ca2+ concentrations, TG2 may function
as a G-protein or as a protein disulfide isomerase, thus con-
tributing to the functionality of mitochondrial respiratory chain
complexes (Nurminskaya and Belkin, 2012). Increased levels of
TG2 are observed in several human pathologies including neu-
rodegenerative diseases such as Alzheimer’s, Huntington’s, and
Parkinson’s diseases, as well as in chronic inflammatory condi-
tions (Taylor et al., 2003; Malorni et al., 2008; Iismaa et al., 2009;
Mastrobernardino and Piacentini, 2010). Most proteins involved
in the pathogenesis of neurodegenerative diseases, as huntingtin,
ataxin1, tau, and alpha-synuclein, were reported to be TG2 sub-
strates (Mastrobernardino and Piacentini, 2010). Increased TG2
expression has also been reported for glioblastomas, malignant
melanomas, and pancreatic ductal adenocarcinomas. Moreover,
TG2 expression is often associated with an increased metastatic
activity or acquisition of drug-resistance (Antonyak et al., 2004;
Karin and Greten, 2005; Kim et al., 2006; Satpathy et al., 2007).
In CF airway epithelial cells, TG2 undergoes small ubiqui-
tin like-modifier (SUMO)ylation (Luciani et al., 2009), a post-
translational modification that affects the stability and functions
of proteins. SUMOylation is a key player of the post-translational
network as it regulates transcription, nuclear translocation, stress
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responses, and chromatin structure. Moreover, it influences intra-
cellular localization and stability of modified proteins (Geiss-
Friedlander and Melchior, 2007; Meulmeester and Melchior, 2008;
Tempè et al., 2008). SUMOylation is accomplished by an enzy-
matic cascade that involves E3 ligases which orchestrate SUMO-
modifications in response to stress. We discovered that the protein
inhibitor of activated STAT (PIAS)y, which is induced by reac-
tive oxygen species (ROS) and participates in the SUMOylation
of NF-κB essential modulator (NEMO) upon genotoxic stress
(Mabb and Wuerzberger-Davis, 2006), is upregulated in CF epithe-
lia in response to oxidative stress and then mediates SUMOyla-
tion of TG2 (Luciani et al., 2009). Indeed, TG2 contains three
SUMO acceptor sites (consensus sequence:ψ_kxE) in its sequence.
SUMOylation of lysines is incompatible with the Ubiquitination
of these residues (Muller and Hoege, 2001). Thus, TG2 SUMOy-
lation ultimately results in the inhibition of TG2 ubiquitination,
thereby preventing its proteasomal degradation. This sustains high
intracellular TG2 protein levels, coupled to prolonged TG2 enzyme
activation as the result of the elevated Ca2+i content. Indeed,
emerging evidence support the role of elevated intracellular cal-
cium concentration in mediating the signaling events that impair
homeostasis in CF epithelia, as reviewed by Antigny et al. (2011a)
in another chapter of this Special Topic. Although the mecha-
nisms underlying the disturbed calcium homeostasis observed in
CF remain incompletely understood, recent studies suggest that
impaired calcium signaling may be the result of either increased
agonist-mediated activation of G-protein-coupled receptors or
abnormal regulation of calcium storage compartments (Egan et al.,
2002, 2004; Ribeiro et al., 2005a,b; Norez et al., 2006a,b; Martino
et al., 2009). Moreover, the abnormal Ca2+ response observed in
CF cells depends on the presence of CFTR at the cell surface and
this reciprocal regulation of CFTR and Ca2+ channels has been
described in the literature (Antigny et al., 2011b).
Therefore, in CF, increased intracellular levels of ROS, induced
by defective CFTR function, lead to the upregulation of the SUMO
E3-ligase PIASy, which facilitates TG2 SUMOylation, persistent
high TG2 protein levels, and sustained TG2 activation as the
result of “permissive” elevated Ca2+ levels. The presence of high
TG2 levels might in turn sustain ROS, as it is known that TG2
may stimulate the activity of the mitochondrial respiratory chains
(Malorni et al., 2008). Remarkably, inhibiting CFTR, either by gene
silencing or by means of pharmacological inhibitors, recapitulates
these post-translational modifications of TG2 through upregu-
lating ROS levels in cell lines expressing wild-type (wt)-CFTR
(Luciani et al., 2009).
These post-translational changes of TG2 protein, induced by
defective CFTR, may have functional implications in epithe-
lial homeostasis. Sustained TG2 activation leads to crosslinking,
increased ubiquitination, and functional sequestration of the TG2
substrates peroxisome proliferator-activated receptor (PPAR)γ
and IκBα (Daynes and Jones, 2002; Kim et al., 2006; Maiuri et al.,
2008). Indeed, the anti-inflammatory molecule PPARγ under-
goes SUMOylation in response to its agonists, thus interacting
with the N-CoR-histone deacetylase (HDAC) 3 co-repressor com-
plex to maintain a repressor condition (Pascual et al., 2005).
TG2-mediated ubiquitination of PPARγ inhibits its SUMOyla-
tion and interaction with N-CoR. Similarly, crosslinking and
ubiquitination of IκBα inhibits IκBα SUMOylation and favors
NF-κB activation and nuclear translocation (Luciani et al., 2009).
Both events were reported to favor inflammation in CF air-
ways. Therefore, TG2 can function as a rheostat of the post-
translational network in response to CF-associated oxidative stress.
TG2 SUMOylation with sustained TG2 activation switches off
the post-translational regulatory mechanisms and perturbs the
intracellular environment (Figure 1).
TG2-mediated protein ubiquitination and crosslinking may
lead to protein aggregation and proteasome overload, thus favor-
ing aggresome formation (Muma, 2007; Dohm et al., 2008).
Misfolded or post-translationally modified proteins that can-
not be degraded by the proteasome machinery can be stocked
in the cytoplasm in the form of aggresomes (Kawaguchi et al.,
2003; Kirkin et al., 2009). Accordingly, ubiquitylated PPARγ
and IκBα aggregates are sequestered within histone-deacetylase
(HDAC)6+/vimentin+ intracellular aggresomes in CF epithelial
cells (Figure 2).
Therefore, proteostasis of F508del-CFTR epithelia is affected
by a combination of genetic defect (resulting from the misfolded
CFTR protein) and post-translational alterations (through the
ROS/TG2 axis).
TG2 is localized in multiple cellular compartments including
cell surface and extracellular matrix. Besides its crosslinking activ-
ity on ECM substrates, extracellular TG2 is also endowed with
PDI, or GTPase functions (Nurminskaya and Belkin, 2012). How-
ever, the potential relevance of the extracellular TG2 in CF is still
unknown.
DEFECTIVE CFTR DISABLES AUTOPHAGY
Given the overproduction of ROS together with the endoplasmic
reticulum (ER) stress induced by the mutant CFTR, one would
expect an activation of autophagy in F508del-CFTR homozy-
gous epithelial cells. Autophagy is pivotal in promoting cellular
clearance of protein aggregates and removal of ROS sources,
such as damaged mitochondria (Mizushima et al., 2008; Kirkin
et al., 2009; Korolchuk et al., 2009; Kroemer et al., 2010; Moreau
et al., 2010). Surprisingly, however, human and mouse CF air-
ways exhibit a pronounced defect in autophagy, as indicated
by reduced autophagosome formation, and the accumulation of
sequestosome 1 (SQSTM1), a major autophagic substrate also
known as p62. This occurs in spite of the normal expression of
major autophagy genes (Luciani et al., 2010, 2011). A defective
autophagic response to bacterial infection has also been reported
in murine CF macrophages. Reduced autophagosome formation
in CF macrophages promotes Burkholderia cenocepacia survival
and hypersecretion of IL-1β (Abdulrahman et al., 2011).
Autophagy results in the lysosomal degradation of cytoplas-
mic organelles or cytosolic components after their sequestration
in two-membraned vesicles (Kroemer et al., 2010; Yang and Klion-
sky, 2010; Codogno et al., 2011; Mizushima et al., 2011). In the last
few years, autophagy has emerged not just as a simply degrada-
tive process, but also as a cellular mechanism essential for the
maintenance of cellular homeostasis and of the energetic balance
(Kroemer et al., 2010). Thus, disabled autophagy is associated with
and is relevant to several human diseases including cancer, viral
infection, neurodegenerative diseases, respiratory pathologies, and
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FIGURE 1 | Defective CFTR-induced perturbation of the
post-translational network in CF epithelial cells. Defective CFTR
leads to increased levels of reactive oxygen species (ROS) that
increase the levels of the SUMO E3-ligase PIASy, causing TG2
SUMOylation, that, in turn, inhibits TG2 ubiquitination, and avoids its
proteosomal degradation, thus sustaining increased TG2 protein levels.
Sustained TG2 activation mediates crosslinking of PPARγ and IκBα,
which undergo ubiquitination and proteasome degradation. This inhibits
nuclear translocation of PPARγ and favors nuclear translocation of
NF-κB, stimulating inflammation.
chronic inflammatory disease (Levine et al., 2011; Rubinsztein
et al., 2011; Sridhar et al., 2012; Patel et al., 2013).
Through which mechanisms is autophagy inhibited in CF?
We have demonstrated that the inhibition of autophagy in CF
epithelial cells is part of the complex perturbation of the post-
translational network consequent to defective CFTR function.
Disabled autophagy in CF epithelial cells is a consequence of TG2-
mediated crosslinking and functional sequestration of BECN1, a
major player of autophagosome formation, which exhibits target
sites (QP, QxxP) for crosslinking by TG2 (Luciani et al., 2010).
BECN1 is a haploinsufficient tumor suppressor protein that
is essential for autophagy (Sinha and Levine, 2008; He and
Levine, 2010; Maiuri et al., 2010). Accumulating evidence indi-
cate that BECN1 dissociates from Bcl-2 during stress conditions,
such as starvation, thus promoting autophagy (Pattingre et al.,
2005; Maiuri et al., 2007, 2010; Axe et al., 2008; Hayashi-Nishino
et al., 2009). Subsequently, BECN1 interacts with the class III
phosphatidyl-inositol 3 kinase (PI3K), human vacuolar protein
sorting (hVps)34 (Matsunaga et al., 2009; Zhong et al., 2009),
facilitating its activation. The ER-associated class III PI3K activ-
ity is crucial for the initiation of autophagosome formation (Axe
et al., 2008; Hayashi-Nishino et al., 2009).
Reduced BECN1/Bcl-2 interaction upon starvation is observed
in CF cells, suggesting an intracellular environment favorable to
autophagy induction. Moreover, BECN1 interacts with the essen-
tial components of the PI3K complex IIIhVps34, hVps15,Ambra1,
as well as with Atg14L, a BECN1 interactor that diverts hVps/Class
III PI3K into an autophagic role (Liang et al., 2008; Matsunaga
et al., 2009). However, in CF epithelial cells, the BECN1 interac-
tome is dislodged away from the ER as a consequence of BECN1
crosslinking and is sequestered within HDAC6+ aggresomes. This
impairs autophagosome formation in CF cells (Luciani et al.,
2010).
Autophagy deficient CF cells accumulate SQSTM1 (p62), an
ubiquitin-binding (and LC3-binding) protein (Bjørkøy et al.,
2005; Kirkin et al., 2009; Mathew et al., 2009; Duran et al.,
2011) that is selectively degraded by autophagy. Autophagy
upregulation has been reported as a compensatory response to
proteasome inhibition, thus revealing a crosstalk between the
proteasome-based and the autophagy-based degradation path-
ways (Komatsu et al., 2007; Kirkin et al., 2009; Korolchuk
et al., 2009; Lamark and Johansen, 2010). SQSTM1 accumu-
lation resulting from autophagy inhibition contributes to pro-
teasome overload and favors aggresome formation, while dis-
abled autophagy inhibits the clearance of such protein aggregates.
Altogether, the combined inhibition of protein and aggresome
turnover may also influence the fate of misfolded CFTR. Indeed,
the enforced expression of F508del-CFTR in CF epithelial cell
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FIGURE 2 |TG2-mediated inhibition of autophagy in CF epithelial
cells. Defective CFTR-mediated TG2 activation leads to BECN1
crosslinking and displaces BECN1 interactome away from the
endoplasmic reticulum (ER). This mislocalization inhibits autophagosome
formation, disables autophagy, and induces accumulation of SQSTM1
(p62). SQSTM1 accumulation leads to proteasome overload and favors
sequestration of cross-linked TG2 substrates (PPARγ, IκBα, BECN1) within
HDAC6+ aggresomes. The combined inhibition of protein and aggresome
turnover may also favor the accumulation of F508del-CFTR (together with
SQSTM1) within HDAC6+/ubiquitin+ intracellular aggregates. Defective
autophagy inhibits the clearance of damaged mitochondria that contribute
to the generation of pro-inflammatory ROS.
lines favors the accumulation of misfolded CFTR (together with
SQSTM1) within HDAC6+/ubiquitin+ intracellular aggregates
(Luciani et al., 2010).
We suggest that this cascade of events can generate a vicious
feed-forward loop, as it impairs the clearance of damaged mito-
chondria, thus increasing ROS generation that in turn enhances
TG2 activation and BECN1 sequestration, further sustaining
airway inflammation (Figure 2).
RESTORING PROTEOSTASIS AMELIORATES LUNG INFLAMMATION
THROUGH RESCUING AUTOPHAGY IN CF
Inhibiting TG2 activity by cystamine (and its reduced form cys-
teamine) or targeting ROS can reduce inflammation in F508del-
CFTR airways, both in vivo in F508del-CFTR homozygous mice
(CftrF508del mice) and in ex vivo using explanted human polyp
biopsies from CF patients (Raia et al., 2005; Luciani et al., 2010).
The effects of cystamine on airway inflammation are medi-
ated by its ability to rescue BECN1 and autophagy, as either
BECN1 depletion used in vitro or administration of the PI3K
complex III inhibitor 3-methyl-adenine (3-MA) used in vivo in
CftrF508del mice, abrogated these beneficial effects of cystamine.
Either enforced BECN1 overexpression or SQSTM1 depletion
in vivo recapitulated the effects of cystamine in ameliorating lung
inflammation in CftrF508del mice (Luciani et al., 2010, 2012). Simi-
larly, cysteamine has already been successfully used in mouse mod-
els of Huntington’s disease to improve disease-related phenotype
(Karpuj et al., 2002).
Importantly, we demonstrated that amelioration of lung
inflammation in CftrF508del mice secondary to cystamine treat-
ment persists up to 10 days beyond cystamine withdrawal, unless
the rescue of BECN1 and autophagy are inhibited by the admin-
istration of 3-MA during washout (Luciani et al., 2012). These
data suggest the provocative hypothesis that, once the cellular
environment has been re-directed toward a physiological status,
a driving force is re-established within the cell, so as to pro-
long these beneficial effects. Could this “newly re-established”
player be the functional CFTR itself at the epithelial surface?
Indeed, manipulating proteostasis might actually improve the
function of misfolded proteins (Balch et al., 2008; Roth and Balch,
2011).
TARGETING AUTOPHAGY AS A NEW STRATEGY TO ENABLE
THE ACTION OF CFTR POTENTIATORS ON F508del-CFTR
F508del-CFTR rescued at the PM by means of corrector strategies
is rapidly dismissed and re-directed to lysosomes for degrada-
tion (Sharma et al., 2004; Okiyoneda et al., 2010, 2011; Lukacs
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and Verkman, 2012). Accordingly, the biochemical half-life of PM
F508del-CFTR is lower than 4 h (Lukacs et al., 1993; Heda et al.,
2001). Therefore, F508del-CFTR is no longer present at the PM
and cannot interact with CFTR potentiators after rescue.
Recently, we have reported that overexpression of BECN1,
administration of cystamine, or depletion of SQSTM1 by RNA
interference, can favor the trafficking of F508del-CFTR pro-
tein to the epithelial cell surface in vitro in CF epithelial
cell lines (CFBE41o- or IB3-1, carrying F508del/F508del or
F508del/W1282X CFTR, respectively), ex vivo in nasal polyp biop-
sies from CF patients, and in vivo in CftrF508del mice. Interestingly,
these treatments can restore a functional CFTR in CF cell lines
and in primary brushed nasal epithelial cells from F508del-CFTR
homozygous patients (Luciani et al., 2012).
Therefore, PR-based strategies in CF (as administration of cys-
tamine or genetic restoration of BECN1) may have a dual effect, as
they reduce lung inflammation while rescuing a functional mutant
CFTR to the epithelial surface.
TARGETING AUTOPHAGY IMPROVES F508del-CFTR PM STABILITY IN
AIRWAY CF EPITHELIA WELL BEYOND DRUGWASHOUT
In addition to its ability to rescue F508del-CFTR, cystamine is
effective in delaying the disposal of PM resident F508del-CFTR
protein and generates permissive conditions to prolong F508del-
CFTR PM residence well beyond cystamine washout. These effects
are mediated by the ability to restore BECN1 and autophagy, as
both BECN1 depletion and 3-MA abrogate the beneficial effects of
cystamine. PM resident mutant F508del-CFTR is still functional
after cystamine withdrawal, as it retains the ability to respond
to forskolin added together with CFTR potentiators (as genis-
tein or VX-532 or VX-770) well beyond the washout period. This
prolonged function of F508del-CFTR was observed in CF cell
lines, as well as in primary brushed nasal epithelial cells from
F508del-CFTR homozygous patients. Moreover, cystamine sus-
tains F508del-CFTR re-location at the lung epithelial surface after
10 days following washout in vivo in CftrF508del mice, unless that
cystamine was combined with 3-MA (Luciani et al., 2012).
These effects of cystamine can explain how the anti-
inflammatory effects as a result of the restoration of autophagy
(either via pharmacological intervention, as cystamine, or by the
enforced expression of BECN1) persist well beyond its withdrawal
in CftrF508del mice. They probably rely on CFTR itself. Indeed, the
pro-autophagic effects of cystamine persist after 10 days following
cystamine withdrawal unless CFTR was depleted during washout,
suggesting that these anti-inflammatory effects are mediated by
the ability to sustain a functional CFTR at the cell surface (Luciani
et al., 2012). Therefore, sustained CFTR function at the PM can
interrupt the cascade of ROS generation, TG2 activation, BECN1
sequestration, and autophagy inhibition, and ultimately reduce
lung inflammation.
These findings could also explain how cystamine, which is not
an autophagy inducer, is highly effective in restoring autophagy
within a “CF environment.” The fact that cystamine can regulate
peripheral proteostasis is also supported by the observation that
cystamine (but not CFTR correctors as VX-325 or Corr-4a) is
effective in sustaining PM stability of F508del-CFTR even if it has
previously been rescued at the PM by low temperature.
TARGETING AUTOPHAGY ENABLES THE BENEFICIAL ACTION OF
POTENTIATORS ON F508del-CFTR
These findings indicate that PRs may be used to rescue and stabilize
F508del-CFTR at the PM of CF epithelial cells. In principle, this
strategy could lower the ER quality control (QC) threshold of all
misfolded proteins, thus interfering with the QC fidelity. However,
besides its effects on F508del-CFTR rescue at the PM, cystamine
can also delay the disposal of PM resident F508del-CFTR pro-
tein. The evidence discussed in this review supports that defective
CFTR suppresses autophagy within the CF epithelial environment
(though the ROS/TG2 pathway), and, conversely, that rescuing
autophagy can restore a functional CFTR at the PM. Altogether,
these insights suggest the existence of a vicious cycle in which
defective CFTR functions destabilizes the CFTR protein and that
can be interrupted by cystamine.
Considering these factors, one would expect that sustaining
PM residence of F508del-CFTR by PRs, could allow potentiators
to improve Cl− transport though PM resident CFTR molecules.
Indeed, our recent data indicate that, if proteostasis has been pre-
viously restored by cystamine, potentiators can become effective
in sustaining the anti-inflammatory effects of cystamine in vivo
in CftrF508del mice. Importantly, genistein, which has no effects
on its own in CftrF508del mice, synergistically interacts with cys-
tamine to reduce lung inflammation triggered by the challenge
with lipopolysaccharide (LPS) from Pseudomonas aeruginosa. The
same effects are observed if proteostasis has been previously re-
established in CftrF508del mice by means of genetic manipula-
tions, such as lentiviral expression of BECN1 or shRNA-mediated
depletion of SQSTM1 (Luciani et al., 2012).
These observations indicate that pharmacological measures
that ameliorate the cellular environment in which mutant CFTR
traffics, instead of specifically targeting the misfolded protein itself,
can result in improved disease outcome.
PERSPECTIVES
CFTR-REPAIRING STRATEGIES AND ANTI-INFLAMMATORY THERAPIES:
TWO SIDES OF THE SAME COIN?
The data discussed in this review suggest that different approaches
could be envisaged to control CF lung inflammation. Some ther-
apies focus on conventional or emerging anti-inflammatory mol-
ecules, downstream of CFTR. Others, as cystamine and other
yet-to-be-developed PRs, rely on the rescue and stabilization of
functional CFTR at the PM. Apparently, cystamine can interrupt
the dangerous cycle leading to lung inflammation, thus opening a
new scenario in the search of the most appropriate CFTR-repairing
strategy.
Searching the appropriate CFTR corrector is a challenging issue
in drug development. An ideal drug candidate for the treatment of
F508del-CFTR patients should not only aim at rescuing trafficking
of mutant CFTR, be it through the conventional Golgi-mediated
exocytic pathway (Ward et al., 1995; Quinton, 1999; Amaral, 2004,
2011) or the unconventional GRASP-dependent secretory path-
way (Gee et al., 2011), but also at sustaining the rescued mutant
CFTR at the PM, to allow the combined action of potentiators on
PM resident F508del-CFTR. Ideally, one single molecule should be
endowed with all these properties to minimize undesirable effects.
Our recent observations suggest that F508del-CFTR patients could
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be sequentially treated with two single pharmacological agents,
first with cystamine and then with CFTR potentiators.
The findings discussed in this review also highlight the impor-
tance of testing F508del-CFTR correctors for their capacity to exert
a prolonged control of lung inflammation in pre-clinical mod-
els, before initiating clinical trials. So far, our strategy has been
successfully tested in nasal polyp biopsies from F508del-CFTR
homozygous patients as well as in vivo in F508del-CFTR homozy-
gous mice (Luciani et al., 2012). At this stage, clinical trials on CF
patients are justified.
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